Prognostic impact of KRAS mutation status for patients with stage IV adenocarcinoma of the lung treated with first-line pembrolizumab monotherapy.
作者： W. Timens , L.E.L. Hendriks , A.J. de Langen , W.H. van Geffen , B.J.W. Venmans
DOI: 10.1016/J.LUNGCAN.2021.04.001
关键词:
摘要: Abstract Objectives Monotherapy with pembrolizumab is the preferred first-line treatment for metastatic non-small cell lung cancer programmed death-ligand 1 (PD-L1) expression ≥50 %, without targetable oncogenic drivers. Although targeted therapies are in development patients specific Kirsten rat sarcoma (KRAS) mutations, these not available daily care yet. It clear whether there a difference survival on high PD-L1 status or KRAS mutation. We aim to compare this based real-world data. Materials and methods This retrospective population-based study using data from Netherlands Cancer Registry. selected stage IV adenocarcinoma % diagnosed between January 2017 December 2018, treated pembrolizumab. Patients EGFR ALK translocations ROS1 rearrangements were excluded. The primary outcome parameter was overall survival. Results 388 (57 %) of 595 had seen more frequently women than men (65 versus 49 respectively, p Conclusion mutated wild-type patients, monotherapy, similar, suggesting that has no prognostic value respect
sci-hub.st 参考文章(47)
Helena A. Yu, Camelia S. Sima, Ronglai Shen, Samantha Kass, Justin Gainor, Alice Shaw, Megan Hames, Wade Iams, Jonathan Aston, Christine M. Lovly, Leora Horn, Christine Lydon, Geoffrey R. Oxnard, Mark G. Kris, Marc Ladanyi, Gregory J. Riely, Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas Journal of Thoracic Oncology. ,vol. 10, pp. 431- 437 ,(2015) , 10.1097/JTO.0000000000000432
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado, Fabrice Barlesi, Martin Kohlhäufl, Oscar Arrieta, Marco Angelo Burgio, Jérôme Fayette, Hervé Lena, Elena Poddubskaya, David E Gerber, Scott N Gettinger, Charles M Rudin, Naiyer Rizvi, Lucio Crinò, George R Blumenschein Jr, Scott J Antonia, Cécile Dorange, Christopher T Harbison, Friedrich Graf Finckenstein, Julie R Brahmer, None, Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 373, pp. 1627- 1639 ,(2015) , 10.1056/NEJMOA1507643
S. Dearden, J. Stevens, Y.-L. Wu, D. Blowers, Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap) Annals of Oncology. ,vol. 24, pp. 2371- 2376 ,(2013) , 10.1093/ANNONC/MDT205
Ferdinandos Skoulidis, Lauren A Byers, Lixia Diao, Vassiliki A Papadimitrakopoulou, Pan Tong, Julie Izzo, Carmen Behrens, Humam Kadara, Edwin R Parra, Jaime Rodriguez Canales, Jianjun Zhang, Uma Giri, Jayanthi Gudikote, Maria A Cortez, Chao Yang, Youhong Fan, Michael Peyton, Luc Girard, Kevin R Coombes, Carlo Toniatti, Timothy P Heffernan, Murim Choi, Garrett M Frampton, Vincent Miller, John N Weinstein, Roy S Herbst, Kwok-Kin Wong, Jianhua Zhang, Padmanee Sharma, Gordon B Mills, Waun K Hong, John D Minna, James P Allison, Andrew Futreal, Jing Wang, Ignacio I Wistuba, John V Heymach, None, Co-occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities Cancer Discovery. ,vol. 5, pp. 860- 877 ,(2015) , 10.1158/2159-8290.CD-14-1236
D. Planchard, S. Popat, K. Kerr, S. Novello, E.F. Smit, C. Faivre-Finn, T.S. Mok, M. Reck, P.E. Van Schil, M.D. Hellmann, S. Peters, Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † Annals of Oncology. ,vol. 29, pp. 192- 237 ,(2010) , 10.1093/ANNONC/MDY275
Biagio Ricciuti, Giulia Costanza Leonardi, Giulio Metro, Francesco Grignani, Luca Paglialunga, Guido Bellezza, Sara Baglivo, Clelia Mencaroni, Alice Baldi, Daniela Zicari, Lucio Crinò, Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications Expert Review of Respiratory Medicine. ,vol. 10, pp. 53- 68 ,(2016) , 10.1586/17476348.2016.1115349
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn, Margarita Majem, Mary J Fidler, Gilberto de Castro, Marcelo Garrido, Gregory M Lubiniecki, Yue Shentu, Ellie Im, Marisa Dolled-Filhart, Edward B Garon, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. ,vol. 387, pp. 1540- 1550 ,(2016) , 10.1016/S0140-6736(15)01281-7
Julien Mazieres, Jean-Philippe Merlio, Didier Debieuvre, Jean Mosser, Hervé Lena, L'Houcine Ouafik, Benjamin Besse, Isabelle Rouquette, Virginie Westeel, Fabienne Escande, Isabelle Monnet, Antoinette Lemoine, Rémi Veillon, Hélène Blons, Clarisse Audigier-Valette, Pierre-Paul Bringuier, Régine Lamy, Michèle Beau-Faller, Jean-Louis Pujol, Jean-Christophe Sabourin, Frédérique Penault-Llorca, Marc G Denis, Sylvie Lantuejoul, Franck Morin, Quân Tran, Pascale Missy, Alexandra Langlais, Bernard Milleron, Jacques Cadranel, Jean-Charles Soria, Gérard Zalcman, Fabrice Barlesi, Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) The Lancet. ,vol. 387, pp. 1415- 1426 ,(2016) , 10.1016/S0140-6736(16)00004-0
Stephanie Y. Brule, Khalid Al-Baimani, Hannah Jonker, Tinghua Zhang, Garth Nicholas, Glenwood Goss, Scott A. Laurie, Paul Wheatley-Price, Palliative systemic therapy for advanced non-small cell lung cancer: Investigating disparities between patients who are treated versus those who are not. Lung Cancer. ,vol. 97, pp. 15- 21 ,(2016) , 10.1016/J.LUNGCAN.2016.04.007
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O’Brien, Suman Rao, Katsuyuki Hotta, Melanie A Leiby, Gregory M Lubiniecki, Yue Shentu, Reshma Rangwala, Julie R Brahmer, None, Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer The New England Journal of Medicine. ,vol. 375, pp. 1823- 1833 ,(2016) , 10.1056/NEJMOA1606774